One-year intensive lifestyle intervention and improvements in health-related quality of life and mental health in persons with type 2 diabetes: a secondary analysis of the U-TURN randomized controlled trial

Christopher Scott MacDonald, Sabrina M Nielsen, Jakob Bjørner, Mette Y Johansen, Robin Christensen, Allan Vaag, Daniel E Lieberman, Bente Klarlund Pedersen, Henning Langberg, Mathias Ried-Larsen, Julie Midtgarda

ABSTRACT

Introduction The effects of lifestyle interventions in persons with type 2 diabetes (T2D) on health-related quality of life (HRQoL) and subjective well-being are ambiguous, and no studies have explored the effect of exercise interventions that meet or exceed current recommended exercise levels. We investigated whether a 1-year intensive lifestyle intervention is superior in improving HRQoL compared with standard care in T2D persons.

Research design and methods We performed secondary analyses of a previously conducted randomized controlled trial (April 2015 to August 2016). Persons with non-insulin-dependent T2D (duration ≤10 years) were randomized to 1-year supervised exercise and individualized dietary counseling (ie, ‘U-TURN’), or standard care. The primary HRQoL outcome was change in the 36-item Short Form Health Survey (SF-36) physical component score (PCS) from baseline to 12 months of follow-up, and a key secondary outcome was changes in the SF-36 mental component score (MCS).

Results We included 98 participants (U-TURN group=64, standard care group=34) with a mean age of 54.6 years (SD 8.9). Between-group analyses at 12-month follow-up showed SF-36 PCS change of 0.8 (95% CI −0.7 to 2.3) in the U-TURN group and deterioration of 2.4 (95% CI −4.6 to −0.1) in the standard care group (difference of 3.2, 95% CI 0.5 to 5.9, p=0.02) while no changes were detected in SF-36 MCS. At 12 months, 19 participants (30%) in the U-TURN group and 6 participants (18%) in the standard care group achieved clinically significant improvement in SF-36 PCS score (adjusted risk ratio 2.6, 95% CI 1.0 to 4.5 corresponding to number needed to treat of 4, 95% CI 1.6 to infinite).

Conclusion In persons with T2D diagnosed for less than 10 years, intensive lifestyle intervention improved the physical component of HRQoL, but not the mental component of HRQoL after 1 year, compared with standard care.

Trial registration number NCT02417012.

Significance of this study

What is already known about this subject?

► The effects of lifestyle intervention in persons with type 2 diabetes (T2D) on mental health-related quality of life (HRQoL) and subjective well-being (SWB) are not clear, and little is known about the effects of longer term lifestyle interventions with high volumes of exercise (at or greater than current recommended levels) on HRQoL and SWB.

► No long-term randomized control studies exploring HRQoL and SWB have used objectively measured levels of exercise or adherence.

What are the new findings?

► Lifestyle intervention with high volumes of exercise results in modest improvements in physical HRQoL compared with standard care, partly due to a deterioration in the standard care group.

► Lifestyle intervention with high volumes of exercise has no significant effect on either mental HRQoL or SWB, potentially due to relatively high baseline scores.

How might these results change the focus of research or clinical practice?

► Persons with short-standing T2D and no diabetes-related complications will likely not experience any major improvements in mental HRQoL or SWB via lifestyle intervention, even when significant reductions in the need for glucose-lowering medications are achieved; potentially reducing chances for long-term adherence.

► Future studies should explore the effects of lifestyle intervention on HRQoL and SWB in persons with T2D with diabetes-related complications and/or compromised levels of HRQoL and SWB.
BACKGROUND

Improving health-related quality of life (HRQoL) and subjective well-being (SWB) should be a central aspect in the care of persons with type 2 diabetes (T2D) given that persons with poor mental health show lower adherence to treatment and lower glycemic control leading to increased risk of long-term complications.4

The recommended management strategies of T2D include lifestyle changes (diet, exercise, and weight loss) prior to or in parallel with the initiation of pharmacological therapy.5 Lifestyle changes, specifically exercise, have shown to improve mental health especially in people with overt depression and anxiety.6 7 Various psychosocial (eg, self-efficacy) or biological (eg, neuroplasticity) hypotheses have been suggested to explain the positive effects of exercise on mental health.6 However, the effects of exercise on persons’ reported well-being in persons with T2D have been mixed.8 The Look AHEAD (Action for Health in Diabetes) study is the largest and longest running study in persons with T2D designed to determine if weight loss achieved through lifestyle reduces the risk of cardiovascular mortality and morbidity.9 A 1-year follow-up study reported reduced symptoms of depression,10 as well as improved HRQoL,11 specifically in relation to the physical component of HRQoL,12 in the intervention group of the Look AHEAD study. A recent systematic review involving persons with T2D found that 15 out of 20 studies showed a positive effect of aerobic exercise on QoL, whereas the effect of resistance training was mixed.13 Analyses of the Italian Diabetes and Exercise Study (IDES) reported that persons with T2D found that 15 out of 20 studies showed a positive effect of aerobic exercise on QoL, whereas the effect of resistance training was mixed.14 Analyses of the Italian Diabetes and Exercise Study (IDES) reported that to achieve significant improvement in physical HRQoL, the exercise volume had to be at least 17.5 MET hours/week (corresponding to approximately 210 min of moderate exercise per week).14 This exercise volume exceeds current minimum exercise recommendations of 150 min of moderate to vigorous aerobic exercise, and two to three strength training sessions per week.15 A limited number of studies have specifically explored if exercise and HRQoL are associated in a dose-dependent manner. These studies indicate that higher exercise levels are associated with higher HRQoL.16 17

However, methodological issues in relation to design, exercise adherence, and study duration make the interpretation of earlier studies challenging. The vast majority of studies have prescribed exercise volumes that are lower, or near current minimum exercise recommendations. Thus, very little is known about the potential benefits (or harms) of exercise volumes exceeding current recommendations. Therefore, the mixed results so far relating the effects of exercise on HRQoL could be a result of few studies exploring the effects of exercise levels exceeding the current minimum recommendation. Recently, we reported the results from a 12-month intensive lifestyle intervention (ie, ‘U-TURN’ intervention), which employed exercise volumes two times greater than current recommendations. The results showed that T2D persons had a higher likelihood of achieving discontinuation of glucose-lowering medications while maintaining optimal HbA1c levels, compared with persons receiving standard care.18 However, the effect on HRQoL was not reported. Using protocolized HRQoL data obtained in U-TURN, the aim of the present study was to investigate whether the ‘U-TURN’ intervention may be superior in improving HRQoL and/or mental health compared with standard care in persons with T2D.

METHODS

Study design

The original trial (U-TURN) is registered at ClinicalTrials.gov, and a detailed description of the study protocol and primary results have been published previously. In brief, the U-TURN study was a single-center, assessor-blinded, two-arm, parallel-group trial designed to test whether an intensive lifestyle intervention was equally effective in maintaining glycemic control compared with standard care in persons with T2D in the Capital Region of Denmark.18 Participants were randomized in a 2:1 ratio in permuted blocks of 3 and 6, stratified by sex. The 12-month follow-up was finalized in August 2016 and the primary results were published in 2017.18 For this study, a prespecified statistical analysis plan was developed prior to conducting any of the secondary analyses (online supplemental material 1).

Participants and eligibility

In brief (see ref 18 19 for details), 98 participants were included in the U-TURN study. Participants recruited to the study were diagnosed with T2D within the last 10 years, aged 218 years, and had a body mass index of ≥25 but ≤40 kg/m². Exclusion criteria were severe comorbidities and/or insulin usage or HbA1c >9% (75 mmol/mol).

Prior to baseline measurements, participants had their glucose-lowering, lipid-lowering, and blood pressure-lowering medications titrated by the study endocrinologist according to prespecified treatment targets.

Intervention

The U-TURN intervention has previously been described in detail.19 In brief, both groups received standard care, consisting of medical counseling, lifestyle advice, and education in T2D provided by a study nurse at baseline and every third month during the 12-month intervention period.

In addition, the U-TURN group received two primary interventions: increased levels of structured exercise and individualized meal plans. The recommended training volume in the intervention was prescribed to reach 240–300 min of aerobic training/week and two or three resistance training sessions/week. All training was performed in groups and supervised across the study period. Supervision was gradually reduced and supported by online supervision. A clinical dietician prepared individual meal plans and the implementation was continuously discussed during group sessions (same groups as...
the training groups) and during individual counseling. In addition, four supportive interventions were applied: support of increased sleep duration, support of increased levels of daily physical activity, self-monitoring of behaviors related to the other interventions, and diabetes management and education.

**Measurements**

HRQoL was assessed using the 36-item Short Form Health Survey (SF-36), version 1. This 36-item generic questionnaire consists of eight subscales (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, mental health), which can be further aggregated into a physical component score (PCS) and mental component score (MCS). Scores have a mean of 50 and an SD of 10 in the US general population with higher scores indicating better health. In Denmark, general population studies have found slightly better mean scores: PCS=52 and MCS=54. The SF-36 has been used in many studies with persons with diabetes and has shown good reliability, known groups validity, predictive validity, and responsiveness to change.

Well-being was assessed using the Mental Health Continuum-Short Form (MHC-SF) and the Warwick-Edinburgh Mental Well-Being Scale (WEMWBS). The MHC-SF is a 14-item generic questionnaire measuring emotional, social, and psychological well-being. Each item is scored on a 6-point Likert scale with higher scores indicating better well-being and mental health. The MHC-SF has shown high internal consistency, discriminant validity, and has been shown to be highly reliable over time. The MHC-SF categorizes three levels of positive mental health: flourishing, moderate, or languishing. A diagnosis of flourishing mental health requires that the participant experience ‘every day’ or ‘almost every day’ at least 1 out of 3 signs of hedonic well-being and in addition 6 of 11 possible signs of positive functioning during the past 4 weeks. A diagnosis of languishing requires the participant to experience ‘never’ or ‘once or twice’ at least one of the measures of hedonic well-being and low levels on at least 6 of the 11 signs of positive functioning. Participants that are neither flourishing nor languishing are diagnosed as having moderate mental health. The WEMWBS is a 14-item generic scale measuring mental health and mental well-being with Likert scale response options for each item ranging from 1 (none of the time) to 5 (all of the time). Total scores can range from 14 to 70, with higher scores indicating better mental well-being and health. The WEMWBS has shown high internal consistency and has been found appropriate to use in the Danish population. Mood was assessed using the Global Mood Scale (GMS). The scale consists of positive (eg, active) and negative terms (eg, helpless) that each is rated on a 5-point Likert scale from 0 (not at all) to 4 (extremely). Scores on both the negative affect and positive affect scales range from 0 to 40. Both the negative affect and positive affect scales of the GMS are internally consistent.

All measurements (ie, SF-36, MHC-SF, WEMWBS, GMS) were self-reported and assessed at baseline, and at 6, 8, 10, and 12-month follow-up, except for WEMWBS, which was assessed only at baseline and at 12-month follow-up. All assessments were carried out in parallel to collection of physiological data in the parent trial (U-TURN) (ie, same time points except for 8 and 10-month follow-up). All exercise and physical activity data were registered via a Polar V800 watch (Finland). Participants were instructed to wear the watch 24 hours/day throughout the intervention. Details of exercise volume measurement methods were described in the prepublished protocol.

Assessments were performed in one laboratory and the biochemical analyses were completed at the central laboratory (Rigshospitalet, Denmark) using standard procedures.

**Outcomes**

The primary outcome was change in the PCS from baseline to 12-month follow-up. Key secondary outcomes include change in MCS from baseline to 12-month follow-up and the proportion of responders, that is, participants achieving a clinically significant improvement from baseline to 12-month follow-up in PCS: defined as a component score ≥3.4 point change, and MCS: defined as a component score ≥1.6 point change. Exploratory outcomes include change in the SF-36 subscales, MHC-SF total score, MHC-SF categorical score, change in WEMWBS, and change from baseline in the positive and negative affect scores derived from the GMS, all at 12 months of follow-up.

**Sample size and power considerations**

No formal power or sample size analyses were performed for the present secondary analysis study. However, for a two-sample pooled t-test of a normal mean difference with a two-sided significance level of 0.05, a total sample size of 96 (allocation ratio of 2:1) has a 95.5% likelihood to detect a statistically significant standardized mean difference (SMD) of 0.8 (36). An SMD is the ratio between the group difference and the pooled SD, and an SMD of 0.8 is considered a large effect. Also, the study would have a power of approximately 80% to detect SMD of 0.6 (moderate effect size). Thus, assuming that 98 participants will be available from the intention-to-treat (ITT) population (64 vs 34), we should have sufficient statistical power (>80%) to detect a statistically significant difference between the groups corresponding to a moderate to large effect size.

**Statistical analysis**

The primary analysis was based on the ITT population including all randomized participants with available data at baseline. Missing data were handled indirectly using mixed models that provide valid statistical inference assuming that data are ‘Missing At Random’. A repeated measures linear mixed model was used including the participant as a random effect factor; fixed effects were
treatment group (two levels), time (five levels), the interaction between treatment group and time, and the value of the outcome at baseline. A gatekeeping procedure using serial testing was applied to adjust multiplicity. The analyses were performed in sequence until one of the analyses failed to show a significant difference or all analyses had been completed at a statistical significance level of 0.05 (two tailed).

Categorical changes for dichotomous endpoints as well as categorical endpoints were analyzed with the use of logistic regression with participant as a random effect, and treatment group, time, the interaction between treatment group and time, and the value of the outcome (on a continuous scale) at baseline as fixed effects (similar to the analyses of continuous outcomes). From the logistic regression models, the resulting OR values and 95% CIs were converted into approximate risk ratios (RR). From the RRs, we estimated the absolute risk difference (RD), which was used to estimate the number needed to treat (NNT) by taking the reciprocal of the RD. The NNT communicates the effect size in absolute terms by indicating how many persons with diabetes that on average must be managed with the U-TURN intervention rather than standard care to achieve one additional good outcome.

Sensitivity analyses included non-responder imputation of missing data (ie, ‘Baseline Observation Carried Forward’) and crude analysis of the potentially biased per-protocol population. The per-protocol population was defined specifically by adherence to medication and attendance to medical consultations, and for the U-TURN group, specifically, attendance to 70% or more of the prescribed exercise sessions. Further details are available in the statistical analysis plan (online supplemental material 1). All analyses were performed in the statistical program R (V.3.5.1), with the packages lme4 and nlme.

RESULTS

A total of 98 participants were included, 64 in the U-TURN group and 34 in standard care (figure 1). At baseline, participants had a mean age of 54.6 years (SD 8.9) and SF-36 PCS median score of 55.1 points (IQR 49.7–57.7) (table 1). In total, three participants had depression at baseline: two in the standard care group

![Flow of participants through the study. BMI, body mass index; HbA1c, glycated hemoglobin A1c; StC, standard care.](image-url)
and one in the U-TURN group. Of these, only the participant in the U-TURN group reported receiving antidepressant medical treatment at baseline.

From baseline to 12-month follow-up, the U-TURN group reported a mean change of 0.8 (95% CI −0.7 to 2.3) in PCS scale, while the standard care group reported a mean decline in PCS score of 2.4 (95% CI −4.6 to −0.1). The corresponding difference between groups was 3.2 (95% CI 0.5 to 5.9, p=0.020) in favor of the U-TURN intervention (table 2).

According to the trajectories, the difference between groups mainly appeared at 12-month follow-up (figure 2).

In the U-TURN group, 19 (30%) participants reported a clinically significant improvement in the PCS score (ie, responders) at 12-month follow-up compared with 6 (18%) participants in the standard care group, with an OR of 4.04 (95% CI 0.94 to 17.43, p=0.061) adjusted for baseline PCS. This means that the participants in the U-TURN group have four times the odds of responding compared with the participants in the standard care group, but the CI is very wide and includes 1 (ie, no statistically significant difference between the groups). The estimated OR corresponds to an adjusted RR of 2.6 (95% CI 1.0 to 4.5) and an NNT was accordingly 4 (95% CI 1.6 to infinite). No difference was observed for the change in MCS, nor for the proportion achieving clinically significant improvements in the PCS score. The sensitivity analyses using the per-protocol population (table 3) and the single-imputation non-responder technique of missing data confirmed the robustness of these findings (online supplemental table 1).

For the exploratory outcomes, changes in SWB and mood were not significantly different in the U-TURN group compared with the standard care group.

### Table 1 Baseline characteristics for the intention-to-treat population

<table>
<thead>
<tr>
<th></th>
<th>n (Intervention)</th>
<th>n (Standard care)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female, n (%)</td>
<td>64 (31 (48))</td>
<td>34 (16 (47))</td>
</tr>
<tr>
<td>Age at consent (years)</td>
<td>64 53.6 (9.12)</td>
<td>34 56.6 (8.1)</td>
</tr>
<tr>
<td>T2D duration, median (IQR), years</td>
<td>64 4.5 (3–7.5)</td>
<td>34 6 (3–9)</td>
</tr>
<tr>
<td>Educational level, median (IQR), years</td>
<td>64 4 (3–4)</td>
<td>34 4 (3–4)</td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td>64 49.2 (9.13)</td>
<td>34 50.1 (9.5)</td>
</tr>
<tr>
<td>2-hour glucose (mg/dL)</td>
<td>62 15.3 (4.06)</td>
<td>33 16.3 (4)</td>
</tr>
<tr>
<td>Body mass (kg)</td>
<td>64 94.7 (14.3)</td>
<td>34 98.1 (15)</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>64 31.4 (3.9)</td>
<td>34 32.5 (4.5)</td>
</tr>
<tr>
<td>VO_{max} (mL O₂/min)</td>
<td>64 2713.2 (717.2)</td>
<td>33 2635.8 (742.8)</td>
</tr>
<tr>
<td>Relative VO_{max} (mL O₂/kg/min)</td>
<td>64 28.7 (6.7)</td>
<td>33 26.9 (6.2)</td>
</tr>
<tr>
<td>MHC-SF (points)</td>
<td>63 54.4 (10)</td>
<td>33 51.6 (13.4)</td>
</tr>
<tr>
<td>Languishing, n (%)</td>
<td>0 (0)</td>
<td>2 (6)</td>
</tr>
<tr>
<td>Moderately mentally healthy, n (%)</td>
<td>15 (24)</td>
<td>7 (21)</td>
</tr>
<tr>
<td>Flourishing, n (%)</td>
<td>48 (78)</td>
<td>24 (73)</td>
</tr>
<tr>
<td>WEMWBS (points)</td>
<td>58 55.9 (6.2)</td>
<td>25 53.8 (9)</td>
</tr>
<tr>
<td>SF-36 PCS, median (IQR), points</td>
<td>64 55.6 (50.4–57.8)</td>
<td>34 54.7 (47.9–57.5)</td>
</tr>
<tr>
<td>SF-36 MCS, median (IQR), points</td>
<td>64 56.2 (52.9–59.0)</td>
<td>34 51.7 (41.7–57.7)</td>
</tr>
<tr>
<td>SF-36 Physical functioning, median (IQR), points</td>
<td>64 55.1 (52.9–57.1)</td>
<td>34 55.0 (48.8–57.1)</td>
</tr>
<tr>
<td>SF-36 Physical role functioning, median (IQR), points</td>
<td>64 56.2 (56.2–56.2)</td>
<td>34 56.2 (49.2–56.2)</td>
</tr>
<tr>
<td>SF-36 Bodily pain, median (IQR), points</td>
<td>64 62.8 (50.8–62.7)</td>
<td>34 55.9 (50.8–62.7)</td>
</tr>
<tr>
<td>SF-36 General health, median (IQR), points</td>
<td>64 53.2 (43.9–57.9)</td>
<td>34 49.7 (38.2–55.6)</td>
</tr>
<tr>
<td>SF-36 Vitality, median (IQR), points</td>
<td>64 58.5 (51.4–65.6)</td>
<td>34 50.2 (44.3–60.9)</td>
</tr>
<tr>
<td>SF-36 Social functioning, median (IQR), points</td>
<td>64 57.1 (54.4–57.1)</td>
<td>34 57.1 (46.3–57.1)</td>
</tr>
<tr>
<td>SF-36 Emotional role functioning, median (IQR), points</td>
<td>64 55.3 (55.3–55.3)</td>
<td>34 55.3 (44.8–55.3)</td>
</tr>
<tr>
<td>SF-36 Mental health, median (IQR), points</td>
<td>64 55.0 (50.4–59.5)</td>
<td>34 49.3 (39.1–61.8)</td>
</tr>
<tr>
<td>GMS Positive affect, median (IQR), points</td>
<td>59 26 (21–31)</td>
<td>28 23 (16–29)</td>
</tr>
<tr>
<td>GMS Negative affect, median (IQR), points</td>
<td>59 6 (2–8)</td>
<td>28 7 (3.5–12)</td>
</tr>
</tbody>
</table>

Data are presented as mean (SD) unless otherwise stated.

*Corresponds to education duration beyond 12th grade.

BMI, body mass index; GMS, global mood scale; HbA1c, glycated hemoglobin A1c; MCS, mental component score; MHC-SF, mental health continuum-short form; PCS, physical component score; SF-36, 36-item short form health survey; T2D, type 2 diabetes; WEMWBS, Warwick-Edinburgh mental well-being scale.
Clinical care/Education/Nutrition

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Between-group comparisons of the changes in the primary, key secondary and exploratory outcomes from baseline to 12-month follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
</tr>
<tr>
<td>Primary outcome</td>
<td></td>
</tr>
<tr>
<td>SF-36 PCS (points)</td>
<td>64</td>
</tr>
<tr>
<td>Key secondary outcomes</td>
<td></td>
</tr>
<tr>
<td>SF-36 PCS responders, n (%)†</td>
<td>61</td>
</tr>
<tr>
<td>SF-36 MCS (points)</td>
<td>64</td>
</tr>
<tr>
<td>SF-36 MCS responders, n (%)†</td>
<td>61</td>
</tr>
<tr>
<td>Other exploratory outcomes</td>
<td></td>
</tr>
<tr>
<td>MHC-SF (points)</td>
<td>63</td>
</tr>
<tr>
<td>Languishing, n (%)</td>
<td>58</td>
</tr>
<tr>
<td>Moderately mentally healthy, n (%)</td>
<td></td>
</tr>
<tr>
<td>Flourishing, n (%)</td>
<td>47 (81)</td>
</tr>
<tr>
<td>WEMWBS (points)</td>
<td>58</td>
</tr>
<tr>
<td>SF-36 Physical functioning (points)</td>
<td>64</td>
</tr>
<tr>
<td>SF-36 Physical role functioning (points)</td>
<td>64</td>
</tr>
<tr>
<td>SF-36 Bodily pain (points)</td>
<td>64</td>
</tr>
<tr>
<td>SF-36 General health (points)</td>
<td>64</td>
</tr>
<tr>
<td>SF-36 Vitality (points)</td>
<td>64</td>
</tr>
<tr>
<td>SF-36 Mental health (points)</td>
<td>64</td>
</tr>
<tr>
<td>SF-36 Emotional role functioning (points)</td>
<td>64</td>
</tr>
<tr>
<td>SF-36 Social functioning (points)</td>
<td>64</td>
</tr>
<tr>
<td>GMS Positive affect (points)</td>
<td>59</td>
</tr>
<tr>
<td>GMS Negative affect (points)</td>
<td>59</td>
</tr>
</tbody>
</table>

For continuous outcomes, estimates are adjusted least squares means (95% CI) from linear mixed models. For dichotomous outcomes, estimates are adjusted ORs (95% CI) from logistic regression with repeated measures. Group-wise estimates for dichotomous outcomes are n (%) at 12-month follow-up. P values in parentheses should be interpreted with caution, since they represent analyses performed after the gatekeeping procedure indicated discontinuation of analyses.

†Responders defined as participants achieving a clinically significant improvement from baseline to 12-month follow-up: PCS improvement ≥3.4 points, MCS improvement ≥4.6 points.
‡Numbers represent the adjusted OR (95% CI).
§Numbers represent the adjusted OR (95% CI) comparing current category to the two other categories combined.
*The model failed to converge.

DISCUSSION

The main finding in this study was that a 12-month lifestyle intervention, including high levels of exercise, significantly improved physical HRQoL in persons with T2D (diagnosis <10 years) compared with standard care. Specifically, 30% of the participants in the U- TURN group compared with 18% in standard care group achieved a change in score considered to represent a clinically significant improvement in regard to physical HRQoL. Despite the improvement in physical HRQoL, mental HRQoL, SWB, and mood were not significantly improved by the intervention.

We hypothesized that the U-TURN intervention would improve HRQoL and SWB. We based this hypothesis on the fact that the U-TURN participants achieved significant reductions in the need for glucose-lowering medications, with more than half of participants being discontinued from medications during the intervention. In addition, participants also managed to maintain glycemic control, improve fitness, and reduce several cardiovascular risk factors. These improvements are potentially important in relation to mental health for several reasons. First, glucose-lowering mediation has been shown to interfere with normal life because it is associated with discomfort and decreased QoL. Second, depression is prevalent in persons with T2D because it is associated with discomfort and decreased QoL. Third, epidemiological evidence suggests that an increased level of physical activity and a healthier diet are associated with better mental health; however, the causal effect is likely being bidirectional. However, the failure of the U-TURN intervention to improve mental outcomes is in line with several previous studies that...
have demonstrated that lifestyle interventions positively influence physical HRQoL in persons with T2D but do not provide improvements in the mental component of HRQoL. In the Diabetes Aerobic and Resistance Exercise trial, a combined exercise group did not show improvements in physical HRQoL compared with controls. The mental HRQoL was not significantly altered; however, due to deterioration in the controls the between-group difference was significant.\(^1\) Also, in the Health Benefits of Aerobic and Resistance Training in Individuals with Type 2 Diabetes study, a randomized 9-month exercise intervention with a control and three different exercise groups (aerobic, resistance and aerobic plus resistance training), it was reported that every intervention group demonstrated greater improvements in physical HRQoL compared with controls, but that the changes in mental HRQoL did not differ significantly between any of the intervention groups and controls at 9-month follow-up.\(^2\)

The longest running study to date, the Look AHEAD study, evaluated the effect of a lifestyle intervention including healthy eating and physical activity aimed at achieving weight loss. During the 8-year follow-up period, physical HRQoL declined in the intervention group as well as in the control group. However, the decline was significantly greater in controls who received standard care.\(^3\) These results align with our findings. In our study, the between-group difference in the PCS was partly due to the decline in the PCS in the standard care group, contrasting with the positive change observed in the intervention group. In support of our results, the Look AHEAD study did not find significant differences between the groups in mental HRQoL at any time during the 8-year follow-up period.\(^4\) The IDES study demonstrated that higher levels of exercise volume increased physical HRQoL; however, the levels of physical activity had to exceed current recommended levels to reach significance.\(^5\) In contrast to our results as well as previous studies, the IDES study also showed an improvement in mental HRQoL at every level of physical activity in the intervention group after 12 months of intervention.\(^6\) This discrepancy could be explained by the fact that the IDES study included participants treated with insulin, and persons with a longer average duration of disease, both of which are indicative of more severe disease states. Both factors have been associated with worse HRQoL.\(^7\) In addition, the baseline levels of mental HRQoL in the IDES study are the lowest of all the studies discussed thus far, and these low baseline scores could explain why the IDES study found improvements in the mental HRQoL, while other studies did not. In other words, the low baseline scores could offer greater room for improvement. In contrast, our study participants had relatively high baseline mental HRQoL scores, the highest among studies discussed here. This difference may reflect a healthier volunteer bias, which would result in the inclusion of a selected subgroup of persons with good mental health at baseline. Although this possible explanation is speculative, the U-TURN intervention was intensive and required participants to allocate significant amounts of time and effort to the program. In addition, participants in the present study had relatively well-regulated glycemic control at baseline and had no severe diabetes-related complications known to be associated with a strong negative impact on HRQoL.\(^8\) Interestingly, while T2D has been associated with lower levels of HRQoL compared with the background population,\(^9\) persons without macrovascular complications appear to have an HRQoL that is relatively unaffected by the disease, and even persons with macrovascular complications appear to experience only small decreases in HRQoL.\(^10\) Another explanation for why mental health did not improve in this study could be that the intensive nature of the intervention blunted potential positive effects on mental health, as the efforts required to comply with the intervention may have resulted in a reduction in the mental HRQoL. The real-world acceptance and adherence to the intensive exercise program may differ across countries, as, for example, in Denmark, 29% are not adherent to the recommendations for physical activity for health compared with 37% in other high-income Western countries.\(^11\) However, since our results align with similar studies discussed here that prescribed lower levels of exercise and less intensive interventions, it is unlikely that the intensive training level obscured an otherwise positive effect on mental HRQoL.

![Figure 2](image-url)
Although speculative, it is possible that lifestyle interventions, in particular increased levels of physical activity and exercise, are effective in improving low affective states, but as our study and the other high-quality studies discussed here show, mental HRQoL and SWB may be relatively resistant to improvement in persons with T2D without major diabetes-related complications or depression.

In healthy populations, lifestyle interventions have demonstrated no or only modest effects on HRQoL. It can be hypothesized that unless an individual is starting with suboptimal mental health, mental health improvements are difficult to achieve due to ceiling effects. This hypothesis is supported by the theory that SWB is under the control of a homeostatic-like mechanism, fitness that is resistant to long-term changes both in a positive and negative direction. SWB is characterized by two unique features: it has a natural positive offset and is highly stable over time. It has been proposed that individuals have a set-point range for SWB that is maintained through a psychological homeostasis system that draws on internal and external factors to maintain a stable level of SWB when challenges arise and overtime. This theory implies that in the absence of pathologies such as depression, long-term positive effects of lifestyle interventions on mental health are likely going to be absent.

There are some limitations to our study. First, the measurement instruments used to assess mental health are generic, and these scales may not be sensitive enough to detect and quantify small changes that are important to persons with T2D or subjective changes specifically related to exercise behavior. Second, exploring mental health was not the primary outcome of the U-TURN study and all findings have

<table>
<thead>
<tr>
<th>Table 3</th>
<th>Between-group comparisons of the changes in the primary, key secondary and exploratory outcomes from baseline to 12-month follow-up for the per-protocol population*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
</tr>
<tr>
<td>Primary outcome</td>
<td></td>
</tr>
<tr>
<td>SF-36 PCS (points)</td>
<td>34</td>
</tr>
<tr>
<td>Key secondary outcomes</td>
<td></td>
</tr>
<tr>
<td>SF-36 PCS responders, n (%)†</td>
<td>34</td>
</tr>
<tr>
<td>SF-36 MCS (points)</td>
<td>34</td>
</tr>
<tr>
<td>SF-36 MCS responders, n (%)†</td>
<td>34</td>
</tr>
<tr>
<td>Other exploratory outcomes</td>
<td></td>
</tr>
<tr>
<td>MHC-SF (points)</td>
<td>34</td>
</tr>
<tr>
<td>Languing, n (%)</td>
<td>32</td>
</tr>
<tr>
<td>Moderately mentally healthy, n (%)</td>
<td>5 (16)</td>
</tr>
<tr>
<td>Flourishing, n (%)</td>
<td>27 (84)</td>
</tr>
<tr>
<td>WEMWBS (points)</td>
<td>32</td>
</tr>
<tr>
<td>SF-36 Physical functioning (points)</td>
<td>34</td>
</tr>
<tr>
<td>SF-36 Physical role functioning (points)</td>
<td>34</td>
</tr>
<tr>
<td>SF-36 Bodily pain (points)</td>
<td>34</td>
</tr>
<tr>
<td>SF-36 General health (points)</td>
<td>34</td>
</tr>
<tr>
<td>SF-36 Vitality (points)</td>
<td>34</td>
</tr>
<tr>
<td>SF-36 Social functioning (points)</td>
<td>34</td>
</tr>
<tr>
<td>SF-36 Emotional role functioning (points)</td>
<td>34</td>
</tr>
<tr>
<td>SF-36 Mental health (points)</td>
<td>34</td>
</tr>
<tr>
<td>GMS Positive affect (points)</td>
<td>33</td>
</tr>
<tr>
<td>GMS Negative affect (points)</td>
<td>33</td>
</tr>
</tbody>
</table>

For continuous outcomes, estimates are adjusted least squares means (95% CI) from linear mixed models. For dichotomous outcomes, estimates are adjusted ORs (95% CI) from logistic regression with repeated measures. Group-wise estimates for dichotomous outcomes are n (%) at 12-month follow-up. P values in parentheses should be interpreted with caution, since they represent analyses performed after the gatekeeping procedure indicated discontinuation of analyses.

*The per-protocol population was defined specifically by adherence to medication and attendance to medical consultations, and for the U-TURN group, specifically, attendance to 70% or more of the prescribed exercise sessions.
†Responders defined as participants achieving a clinically significant improvement from baseline to 12-month follow-up: PCS improvement ≥3.4 points, MCS improvement ≥4.6 points.
‡Numbers represent the adjusted OR (95% CI). §Numbers represent the adjusted OR (95% CI) comparing current category to the two other categories combined.

GMS, global mood scale; MHC-SF, mental health continuum-short form; NA, not applicable; PCS, physical component score; SF-36, 36-item short form health survey; WEMWBS, Warwick-Edinburgh mental well-being scale.
Research in Type 2 Diabetes (the Danish Council for Strategic Research, grants 09-067009 and 09-075724). The Contour Next glucose monitors were provided by Bayer, Copenhagen, Denmark. This work was also supported by a grant from the Danish Diabetes Academy, which is supported by the Novo Nordisk Foundation (MRL). In addition, MYJ received funding from Rigshospitalet. RC and SMN’s employer, the Parker Institute, Bispebjerg and Frederiksberg Hospital, is supported by core grant (OCAY-18-774-0FL) from the Oak Foundation.

Disclaimer The funders had no role in design and conduct of the study; collection, analysis, and interpretation of data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Competing interests AV was appointed vice-president for AstraZeneca’s Translational Research and Early Clinical Development during the completion of the study, but remained in the scientific steering committee of this study. RC and SMN’s employer, the Parker Institute, Bispebjerg and Frederiksberg Hospital, is supported by core grant OCAY-13-309 from the Oak Foundation. RC reports receiving personal fees from AbbV, AbbVie, Amgen, Axellus, Bayer HealthCare Pharmaceuticals, Biogen Idec, Bristol-Myers Squibb, Cambridge Weight Plan, Celgene, Eli Lilly, Hospira, Ipsen, Janssen, Laboratoires Expanscience, and Merck Sharp; personal fees from employment from Research Unit for Musculoskeletal Function and Physiotherapy, Institute of Sports Science and Clinical Biomechanics, and the University of Southern Denmark; grants pending and grant funding from Axellus, AbbV, Cambridge Weight Plan, Janssen, and Merck Sharp; and being involved in many healthcare initiatives and research that could benefit from wide uptake of this publication, including Cochrane, Outcome Measures in Rheumatology, International Dermatology Outcome Measures, RADS, and the Grading of Recommendations Assessment, Development and Evaluation Working Group. MRL received personal speaker fees from Novo Nordisk.

Patient consent for publication Not required.

Ethics approval Guidelines from the Helsinki Declaration were followed and the study was approved by the Scientific Ethical Committee at the Capital Region of Denmark. All participants provided oral and written informed consent.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. Proposals should be directed to MRL (mathias.ried-larsen@regionh.dk). To gain access, data requestors will need to sign a data access agreement.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Christopher Scott MacDonald http://orcid.org/0000-0003-3726-9081
Julie Midggaard http://orcid.org/0000-0003-2381-2127

REFERENCES

Clinical care/Education/Nutrition


The effects of a one-year intensive lifestyle intervention on health-related quality of life and mental health in patients with type 2 diabetes: Statistical Analysis Plan for secondary analyses from the randomized U-TURN trial

Version 1.0 (May 13, 2019)

SAP authors: Christopher Scott MacDonald, Robin Christensen, Sabrina Mai Nielsen, Julie Midtgaard.

Statistical analyst: Sabrina M. Nielsen, MSc; Biostatistics fellow.

Statistical advisor: Robin Christensen, MSc, PhD; Professor of Biostatistics and Clinical Epidemiology; Head of Musculoskeletal Statistics Unit.

Affiliations:
CSM: Department of CopenRehab, Faculty of Health Sciences, Copenhagen University, Copenhagen, Denmark AND Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark
RC: Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen AND Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Denmark
JM: The University Hospitals Centre for Health Research, Copenhagen University Hospital Rigshospitalet, Denmark; Department of Public Health, Section of Social Medicine, University of Copenhagen, Denmark
SMN: Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen AND Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Denmark

Collaborators: Robert Cummins, Henning Langberg, Mathias Ried-Larsen.

Trial registration: NCT02417012
Study population

The primary analyses will be based on the Intention to Treat (ITT) population, based on the Full Analysis Set. The ITT principle asserts the effect of a treatment policy (that is, the planned treatment regimen) rather than the actual treatment given (i.e. it is independent of adherence). This has the consequence that participants allocated to a treatment group should be followed up, assessed and analysed as members of that group irrespective of their compliance to the planned course of treatment (i.e. independent of withdrawals and cross-over phenomena). In general, it is advantageous to demonstrate a lack of sensitivity of the principal trial results to alternative choices of the set of participants analysed. In addition to the ITT-approaches, we will analyse the results as per protocol (described below).

We plan to conduct both an analysis of the full analysis set and a per protocol analysis, so that any differences between them can be explicitly discussed and interpreted. The data analysis based on the per-protocol population will still depend on the group allocation, but will have a stringent definition of whether participants adhered to the prescribed protocol.

We define the per protocol population as:

The particular outcome measure of interest is available both at baseline and at 12-month follow-up (i.e. complete case population). Further, specific for the individual groups:

U-TURN (intervention group)
- Attending at least four (of five [80%]) medical consultations
- Conducting ≥70% of all exercise sessions (supervised and un-supervised – as assessed by the exercise registration)
- Only gets the prescribed medications and/or the prescribed combination of medications according to the treatment algorithm

Standard care (comparator: control group):
- Attending at least four (of five [80%]) medical consultations
- Only gets the prescribed medications and/or the prescribed combination of medications according to the treatment algorithm
**Primary analyses:**

Our primary analyses will be based on the ITT population, including all randomized participants with available data at baseline. Missing data will be handled indirectly and statistically modeled using repeated-measures linear mixed models (see below). These models will be valid if data are ‘Missing at Random’ (MAR): “*Any systematic difference between the missing values and the observed values can be explained by differences in observed data*”. Contrasts between groups will be estimated based on repeated-measures analysis of covariance applied in mixed linear models.

**Statistical methods**

*Sample size considerations:* The sample size in this study (according to the original protocol) was based on what was considered feasible (1) within the local context, and it enabled up to 120 participants to be enrolled in the trial period (29\(^{th}\) of April 2015 to 17\(^{th}\) of August 2017). The sample size of the main-study was truncated at 120 participants or the N reached at the end of the recruitment period. At the end of the recruitment period, 64 patients were randomized to the intervention group and 34 patients to the standard care group (3).

No formal power analysis was performed for the present secondary analysis study. However, assuming that 98 participants will be available from the ITT population (64 vs 34) we should have a sufficient statistical power (>90%) to detect a statistically significant difference between the groups corresponding to a moderate to large clinical effect size in any of the HRQoL domains. According to Cohen’s guidelines for interpreting effect sizes a small effect size is 0.2, a moderate effect size is 0.5, whereas as large effect size is 0.8 (4). For a two-sample pooled t-test of a normal mean difference with a two-sided significance level of 0.05, a total sample size of 96 (allocation ratio of 2 to 1) has a power of 95.5% to statistically detect a standardized mean difference (SMD) of 0.8 (i.e. Cohen’s index). With the expected sample size in the ITT population, the secondary analyses should have a reasonable power to detect even a moderate clinical effect size (Cohen’s index of 0.60 would correspond to a statistical power around 80%).

*Statistical analyses:* The primary statistical model will consist of repeated measures linear mixed models, which state that observed data consist of two parts; fixed effects and random effects. Fixed effects define the expected values of the observations, and random effects define the variance and covariances of the observations. In this study (with secondary analyses) from the U-turn trial with repeated measures, participants were randomly assigned to treatment groups (U-turn vs Standard of
Care), and observations were made at five time points (0, 6, 8, 10, 12) for each participant. Basically, there are two fixed-effect factors: group and time. Random effects result from variation between and within participants. We anticipate that measures on the same patient at different times are correlated, with measures taken close together in time being more highly correlated than measures taken far apart in time; observations on different participants will be assumed independent (5).

The objectives of repeated measure designs are to make inferences about the expected values of the observations, that is, about the means of the populations from which participants are sampled. This is done in terms of treatment and time effects in the model. Data will be analyzed using R, with the particular outcome variable at baseline level as a covariable - using a multilevel repeated measures random effects model with participants as the random effect factor based on a restricted maximum likelihood (REML) model.

The change in the SF36-PCS value will be the (primary) response variable, and the baseline value (one for each participant), treatment group (two levels), and time (five levels) will be included as covariates, as well as the interaction between treatment group and time, and Patient ID as a random effect. This statistical model holds all between-group comparisons at all assessment points (incl. baseline) and allows for evaluation of the average effect, as well as the trajectory over the time period from baseline to 12-month follow-up.

Categorical changes for dichotomous end points will be analyzed with the use of logistic regression with the same fixed effects and covariates as the respective analysis of covariance. Since Odds Ratios (ORs) for outcomes of common incidence either over- or under estimate the corresponding risk estimate, we will convert all the calculated OR values and 95% confidence intervals into approximate Risk Ratios (6). Following these analyses, the proportion of patients experiencing the outcome of interest will be reported for the groups and interpreted based on the number needed to treat (NNT) - communicating the effect size in absolute terms (7). The NNT is computed by taking the reciprocal of the absolute risk difference (RD); the NNT will indicate how many diabetes patients must be managed on average with U-turn intervention rather than standard care to achieve 1 additional good outcome.

For the statistical analyses, we will primarily use the statistical software R (version 3.3.3 or newer) (8) with the packages lme4 (9) and nlme (10). The following codes will be used for the main analyses:

```r
#Primary analysis of primary outcome:
```
```r
lme(SF36PCS_change ~ factor(TIME) + GROUP + factor(TIME)*GROUP + SF36PCS_0, random=~1|PtID, 
corr=corGaus(form=~TIME|PtID,nugget=TRUE), data=d)
```

```r
#Analysis of secondary outcomes:
lme(OutcomeX_change ~ factor(TIME) + GROUP + factor(TIME)*GROUP + OutcomeX_0, random=~1|PtID, 
corr=corGaus(form=~TIME|PtID,nugget=TRUE), data=d)
```

```r
lm(OutcomeY_change ~ GROUP + OutcomeY_0, data = d)
```

```r
glmer(OutcomeZ ~ TIMEfac + GROUP + TIMEfac*GROUP + OutcomeZ_0 + (1 | PtID), data = d, family = binomial)
```

**Analysis populations: Handling of missing data and sensitivity analyses**

As explained above, we plan to conduct both an analysis of the full analysis set (ITT population) and a per protocol analysis, so that any differences between them can be explicitly discussed and interpreted. Robustness is a concept that refers to the sensitivity of the overall conclusions to various limitations of the data, assumptions, and analytic approaches to data analysis. Robustness implies that the treatment effect and primary conclusions of the trial are not substantially affected when analyses are carried out based on alternative assumptions or analytic approaches.

**Sensitivity analyses:** Loss to follow-up and missing data for various reasons is hard to avoid in randomized trials and in particular in trials like the U-turn trial where data collection has been finalized. We will apply the analysis framework suggested by White et al (2011) where missing data related to the ITT approach depends on making plausible assumptions about the missing data and including all participants in subsequent sensitivity analyses (11):

1. Attempt to follow up all randomized participants, even if they withdraw from allocated treatment (i.e., U-turn data collection already finalized)
2. Perform a **main analysis** of all observed data that are valid under a plausible assumption about the missing data (i.e. Model-based: data as observed; using linear mixed models assumes that data are ‘Missing at Random’ [MAR])
3. Perform **sensitivity analyses** to explore the effect of departures from the assumption made in the main analysis (i.e. A non-responder-imputation: using the value at baseline to replace missing data will correspond to a non-responder imputation; these models will potentially be valid even if data are ‘Missing Not At Random’ [MNAR])
4. Account for all randomized participants, at least in the sensitivity analyses (covered by #2 and #3 above plus the corresponding analyses based on the Per protocol population).
The interpretation of the corresponding statistical measures of uncertainty of the treatment effect and treatment comparisons will involve consideration of the potential contribution of bias to the $p$-value, 95% confidence interval, and inference in general (12).

#1+2: Our primary analysis population will be all participants with available data at baseline statistically modelled using repeated-measures linear mixed models (see above). These models will be valid if data are ‘MAR’.

#3+4 Sensitivity: We will analyze all variables with missing data being replaced by imputation of the baseline level; i.e. interpreted as assuming that those who dropped out returned to their baseline level (13). These estimates could potentially be valid even if data are ‘Missing Not At Random’.

Because the degree of potential confounding, when outcomes are missing, cannot be determined (the required data are by definition missing) the only statistically sound approach is sensitivity analyses, which involve assessing the robustness of the result to a range of plausible mechanisms responsible for the missing data (14).

**Multiplicity Considerations**

All applicable statistical tests will be 2-sided and will be performed using a 5% significance level. All confidence intervals presented will be 95% and two-sided. The selection of an appropriate statistical strategy for dealing with multiplicity (repeated statistical tests) is critical for performing reliable inferences and maximizing the probability of an apparent success in a clinical trial like U-Turn. Multiplicity considerations play a central role in the assessment of efficacy evidence in the presence of competing clinical objectives; i.e. the more comparisons that are made, the more likely it is that a comparison that appears to be significant will be falsely so. In order to preserve the family wise error rate of the multiple analyses, the multiplicity of the analyses of the primary and selected secondary efficacy outcomes will be adjusted using a gatekeeping procedure (15). The analyses will be performed in sequence until one of the analyses has failed to show the significant difference or all analyses have been completed at a statistical significance level of 0.05. The sequence of the analyses for the selected secondary efficacy outcomes are listed below.
A result of the this “gate keeping approach” is that formal comparison with respect to the first secondary outcome to be tested (change from baseline in the SF36-PCS responders measured by SF-36 at month 12) will be conducted conditional on the test results for primary efficacy outcome. Thus, if the test of change in SF36-PCS is statistically significant (i.e., two sided p-value ≤ 0.05), then the comparison for change from baseline in the SF36-PCS responders measured by SF-36 at month 12 will be performed at $\alpha = 0.05$. If the test result of SF36-PCS is not statistically significant, the formal statistical tests will not be interpreted as statistically significant for change in SF36-PCS responders at month 12 and for the remaining of secondary/exploratory endpoints.

For planned statistical tests that are not formally considered statistically significant as a result of aforementioned “gate keeping” multiplicity adjustment strategy (15), nominal 2-sided p-values (without adjustment for multiplicity) will still be computed as a measure of the strength of the association between the outcomes and the U-turn effect rather than formal test of hypotheses.
References:

Supporting Material

Stable 1 Sensitivity Analyses: Between-group comparisons of the changes in the primary, key secondary and exploratory outcomes from baseline to 12-month follow-up.

<table>
<thead>
<tr>
<th></th>
<th>n</th>
<th>Intervention</th>
<th>n</th>
<th>StandardCare</th>
<th>Difference</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary outcomes:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SF36-PCS, points</td>
<td>64</td>
<td>0.8 (-0.6 to 2.2)</td>
<td>34</td>
<td>-1.9 (-3.8 to 0.1)</td>
<td>2.6 (0.3 to 5.0)</td>
<td>0.029</td>
</tr>
<tr>
<td><strong>Key secondary outcomes</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SF36-PCS responders, no (%)**</td>
<td>64</td>
<td>19 (30)</td>
<td>34</td>
<td>6 (18)</td>
<td>4.04 (0.94 to 17.43)***</td>
<td>0.061</td>
</tr>
<tr>
<td>SF36-MCS, points</td>
<td>64</td>
<td>-0.3 (-2.2 to 1.7)</td>
<td>34</td>
<td>0.2 (-2.5 to 3.0)</td>
<td>-0.5 (-3.9 to 2.9)</td>
<td>0.762</td>
</tr>
<tr>
<td>SF36-MCS responders, no (%)**</td>
<td>64</td>
<td>16 (25)</td>
<td>34</td>
<td>9 (26)</td>
<td>2.43 (0.29 to 20.55)***</td>
<td>(0.415)</td>
</tr>
<tr>
<td><strong>Other exploratory outcomes</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MHC-SF, points</td>
<td>63</td>
<td>-0.3 (-2.3 to 1.6)</td>
<td>33</td>
<td>1.1 (-1.7 to 3.8)</td>
<td>-1.4 (-4.8 to 2.0)</td>
<td>(0.414)</td>
</tr>
<tr>
<td>Languishing, n (%)</td>
<td>63</td>
<td>3 (5)</td>
<td>33</td>
<td>1 (3)</td>
<td>NA*</td>
<td></td>
</tr>
<tr>
<td>Moderately mentally healthy, n (%)</td>
<td>10 (16)</td>
<td>6 (9)</td>
<td>11 (17)</td>
<td>0.19 (0.04 to 0.97)***</td>
<td>(0.045)</td>
<td></td>
</tr>
<tr>
<td>Flourishing, n (%)</td>
<td>50 (79)</td>
<td>23 (36)</td>
<td>27 (41)</td>
<td>2.93 (0.54 to 15.88)****</td>
<td>(0.212)</td>
<td></td>
</tr>
<tr>
<td>WEMWBS, points</td>
<td>58</td>
<td>2.0 (1.2 to 2.7)</td>
<td>25</td>
<td>2.6 (1.5 to 3.7)</td>
<td>-0.6 (-2.0 to 0.7)</td>
<td>(0.333)</td>
</tr>
<tr>
<td>SF-36 Physical functioning, points</td>
<td>64</td>
<td>1.2 (0.4 to 2.1)</td>
<td>34</td>
<td>-0.9 (-2.0 to 0.3)</td>
<td>2.1 (0.6 to 3.5)</td>
<td>(0.005)</td>
</tr>
<tr>
<td>SF-36 Bodily pain, points</td>
<td>64</td>
<td>-1.4 (-3.3 to 0.6)</td>
<td>34</td>
<td>-3.2 (-5.9 to -0.5)</td>
<td>1.8 (-1.5 to 5.2)</td>
<td>(0.286)</td>
</tr>
<tr>
<td>SF-36 General health, points</td>
<td>64</td>
<td>3.5 (2.0 to 5.0)</td>
<td>34</td>
<td>0.2 (-1.9 to 2.3)</td>
<td>3.3 (0.7 to 5.9)</td>
<td>(0.013)</td>
</tr>
<tr>
<td>SF-36 Physical role functioning, points</td>
<td>64</td>
<td>-1.1 (-2.8 to 0.6)</td>
<td>34</td>
<td>-2.1 (-4.5 to 0.3)</td>
<td>1.0 (-1.9 to 3.9)</td>
<td>(0.504)</td>
</tr>
<tr>
<td>SF-36 Vitality, points</td>
<td>64</td>
<td>2.0 (0.1 to 4.0)</td>
<td>34</td>
<td>-0.3 (-3.1 to 2.4)</td>
<td>2.4 (-1.0 to 5.7)</td>
<td>(0.167)</td>
</tr>
<tr>
<td>SF-36 Mental health, points</td>
<td>64</td>
<td>0.7 (-1.4 to 2.8)</td>
<td>34</td>
<td>-1.0 (-3.9 to 1.9)</td>
<td>1.7 (-1.9 to 5.3)</td>
<td>(0.356)</td>
</tr>
<tr>
<td>SF-36 Emotional role functioning, points</td>
<td>64</td>
<td>-1.4 (-3.2 to 0.5)</td>
<td>34</td>
<td>-0.5 (-3.1 to 2.0)</td>
<td>-0.8 (-4.0 to 2.4)</td>
<td>(0.607)</td>
</tr>
<tr>
<td>SF-36 Social functioning, points</td>
<td>64</td>
<td>-1.0 (-2.6 to 0.7)</td>
<td>34</td>
<td>-0.2 (-2.5 to 2.0)</td>
<td>-0.7 (-3.6 to 2.1)</td>
<td>(0.614)</td>
</tr>
<tr>
<td>GMS Positive affect, points</td>
<td>59</td>
<td>2.3 (0.9 to 3.8)</td>
<td>28</td>
<td>1.0 (-1.0 to 3.1)</td>
<td>1.3 (-1.2 to 3.8)</td>
<td>(0.296)</td>
</tr>
<tr>
<td>GMS Negative affect, points</td>
<td>59</td>
<td>-1.1 (-2.3 to 0.2)</td>
<td>28</td>
<td>-0.6 (-2.4 to 1.2)</td>
<td>-0.5 (-2.7 to 1.7)</td>
<td>(0.667)</td>
</tr>
</tbody>
</table>

For continuous outcomes, estimates are adjusted Least-Squares Means (95% confidence intervals – CI) from linear mixed models. For dichotomous outcomes, estimates are adjusted odds ratios (95% CI) from logistic regression with repeated measures. Group-wise estimates for dichotomous outcomes are n (%) at 12 months follow-up. P-values in parentheses should be interpreted with caution, since they represent analyses performed after the gatekeeping procedure indicated discontinuation of analyses.

*The model failed to converge.

**Responders defined as participants achieving a clinically significant improvement from baseline to 12-month follow-up: PCS improvement ≥3.4 points, MCS improvement ≥4.6 points

***Numbers represent the adjusted odds ratio (95% CI).

****Numbers represent the adjusted odds ratio (95% CI) comparing current category to the two other categories combined.